About Us - Advisory Boards

Scientific Advisory Board

Aimery de Gramont, M.D.

Prof. de Gramont joined the Scientific Advisory Board of PharmaEngine in January 2006. He has been Professor of Oncology, Saint-Antoine Hospital, Paris, France since 1993 and Chief of Services from 2001 to 2014. He is Professor and Chief of Oncology Services at Institut Hospitalier Franco Britannique, Paris since 2014. He has created two cornerstone standard of regimens (FOLFIRI and FOLFOX) for colorectal cancer and chaired many large international trials for colorectal cancers. He is also the President and Founder of GERCOR and ARCAD Foundation in France. He received his M.D. from Faculty of Medicine Laureate, Paris, France.

Alain Herrera, M.D.

Dr. Herrera joined the Scientific Advisory Board of PharmaEngine in November 2008. He created the Foundation of Alain Oncology Consulting in November 2008 after heading for ten years the oncology business at Sanofi-Aventis where he was successively Vice President responsible for Global Oncology Business Strategy and Development (2007-2008) and Head of Global Oncology Franchise (1998-2007) and contributed to the worldwide registration of two products: oxaliplatin (ELOXATINâ) and rasburicase (FASTURTECâ/ELITEKâ) as well as the gastric and head & neck indications for docetaxel (TAXOTEREâ). He received his M.D. from Pitié-Salpétrière Hospital, Faculty of Medicine, Paris, France.

Li-Tzong Chen, M.D., Ph.D.

Prof. Chen collaborated with PharmaEngine for the development of PEP02 since 2004. He is the director of National Institute of Cancer Research, National Health Research Institutes, Taiwan and Professor of National Cheng Kung University and Kaohsiung Medical University, Taiwan. As s a board certified gastroenterologist and medical oncologist, he focuses on the development of innovative strategies for treating prevalent gastrointestinal tract (including, hepatobiliary and pancreas) cancers in Taiwan, through conducting clinical trials and trial-related translational research. He was the key investigator in the NAPOLI-1 phase III study, which resulted in the approval of PEP02/MM-398 for the patients with gemcitabine-treated metastatic pancreatic cancer. He received his M.D. and Ph.D. from Kaohsiung Medical University, Taiwan.

Eric Raymond, M.D., Ph.D.

Prof. Raymond joined the Scientific Advisory Board of PharmaEngine in January 2017. He is the Head of Medical Oncology at Paris Saint-Joseph Hospital Group and Professor of Medical Oncology at Denis Diderot Paris 7 University & consultant in medical oncology at Bichat Hospital. He was the Principal Investigator of > 50 clinical trials, including phase I, II, and III studies. Some of his works were seminal in the development of phase III trials and registration of some drugs such as oxaliplatin, sunitinib, temsirolimus and everolimus. He received his M.D. and Ph.D. from Pierre et Marie Curie Paris 6 University, France.

Clinical Advisory Board

R.K. Hsieh, M.D.

Dr. Hsieh is now Attending Physician and former Chief at the Division of Hematology and Oncology of Mackay Memorial Hospital in Taipei, Taiwan. He is an expert in the clinical development of new drugs in colorectal cancer, breast cancer, lung cancer, prostate cancer and gastric cancer.

C.H. Wang M.D.

Dr. Wang is now Attending Physician at the Division of Hematology and Oncology and former Director of Cancer Center at Chang Gung Memorial Hospital in Keelung, Taiwan. His expertise is the clinical development of new drugs in gastrointestinal cancers and head & neck cancer.